Medical device regulatory information management software: a practical guide for RA teams

Medical device regulatory affairs teams operate at the intersection of dense regulatory frameworks, fragmented product portfolios, and accelerating global market requirements. A regulatory information management (RIM) system purpose-built for devices is the operational backbone that connects product registrations, UDI submissions, post-market obligations, and health authority interactions into a single, auditable structure. This guide is written for regulatory operations managers, RA systems leads, and regulatory data stewards who are evaluating or planning a RIM implementation and need device-specific guidance, not a generic platform overview.

Overview

Medical device regulatory information management software is a centralized platform that provides the digital infrastructure needed to manage regulatory complexity, maintain compliance, and sustain a single source of truth across a manufacturer's global product portfolio. Unlike generic document control or pharma-oriented RIMS platforms, a device-first RIM is structured around the objects that matter most to medtech: device families, product variants, Basic UDI-DI records, registrations per country, submission dossiers, Notified Body certificates, and post-market surveillance obligations. Each of these objects is linked so that a change in one propagates a traceable signal to all dependent records.

The problem a RIM is designed to solve is not document storage alone. Device RA teams working across spreadsheets, shared drives, and disconnected databases consistently face version drift, missed renewal deadlines, and manual status reporting that consumes time that should go toward strategic work. A well-configured RIM replaces that fragmented landscape with structured, role-based workflows, automated deadline alerts, and real-time visibility into registration status across every active market. Large-scale tracking scenarios — for example, monitoring registration status for 100+ product lines across 40+ markets — are operationally unsustainable without structured software.

It is equally important to understand what a device RIM is not. It is not an electronic quality management system (eQMS), a product lifecycle management (PLM) system, or an electronic document management system (EDMS) acting as a repository for design history files. The RIM interacts with all of those systems, but its scope is regulatory operations: the planning, execution, tracking, and reporting of every obligation that connects a device to a health authority. The sections that follow make these boundaries concrete.

What medical device RIM software does—and what it doesn't

A device RIM's core function is to manage the regulatory lifecycle of a product across every market where it is placed or intended for placement, which directly reduces manual tracking effort for RA and RegOps teams. That includes initiating and tracking submissions, managing the approvals that result from those submissions, monitoring renewal and surveillance obligations, and providing an auditable record of every decision and interaction with health authorities. A well-designed platform also connects regulatory intelligence — monitoring changes in standards and regulations — to product records so that when a market updates classification criteria or submission requirements, the impact on active registrations is visible immediately rather than discovered during an audit.

A RIM does not own the design record. The design history file (DHF), risk management file, software lifecycle records, and test reports live primarily in an eQMS or controlled EDMS and are referenced by the RIM rather than duplicated in it. Likewise, a RIM does not own engineering configurations, bills of materials, or component specifications; those belong in PLM. The RIM receives structured output from PLM and eQMS — product identifiers, configuration states, approved document versions — and uses them to assess regulatory impact and maintain accurate submission artifacts. Conflating these roles by trying to make the RIM a catch-all system creates overlapping functionality that increases confusion and degrades data quality.

This distinction matters for validation scope and ongoing maintainability. Extending a RIM into quality-event tracking or design control expands validation effort and makes upgrades more complex. Keeping the RIM focused on regulatory operations makes it easier to validate, audit, and maintain over time.

Core device workflows a RIM must support

A credible medical device RIM software platform must support at least six device-specific workflow categories, which define whether a platform is device-capable or a repurposed pharma tool. Generic RIMS platforms can handle submissions and dossier management, but they typically lack device-specific data structures and workflow templates: UDI master data, Notified Body certificate tracking, EU MDR/IVDR technical documentation structures, and PMS/PMCF/PSUR generation. Evaluating a platform against these workflow areas provides a practical basis for vendor selection.

Registrations and submissions across markets (510(k), De Novo, PMA, EU MDR/IVDR)

Submission management is the most visible function of a device RIM, and it is where differences between platforms become apparent quickly; choosing a platform that models device-specific submission pathways reduces rework and editorial errors. For the US market, a RIM should support distinct submission pathways — 510(k), De Novo, PMA, and IDE — with pathway-specific task templates, artifact checklists, and gate reviews. Each pathway has different required sections, review timelines, and interactive review norms; a single generic submission template is not adequate. For the EU, the RIM should structure both the Annex II (full technical documentation) and Annex III (summary technical documentation) requirements under EU MDR, and the analogous structures for IVDR, with version-controlled document links to the corresponding DHF records held in eQMS.

Worked example — 510(k) submission in a device RIM: A mid-sized cardiovascular device manufacturer with a Class II catheter prepares a new 510(k) for an incremental design change. In the RIM, the submission record is created as a child of the existing device record, inheriting the predicate device linkage and cleared indications for use. The RIM task template pre-populates standard 510(k) sections and assigns section owners from RA, CMC, and biocompatibility teams. As each section is completed and approved in the shared workspace, the gate checklist updates and linked validation flags alert owners to related changes. At submission lock, the RIM generates a completeness report confirming required artifacts before the package is routed to FDA eSTAR. This workflow is operationally impossible to scale reliably in spreadsheet-based trackers once multiple concurrent section owners are involved.

Beyond major submission pathways, a RIM must handle the ongoing registration maintenance that consumes the largest share of RA operations time: annual renewals, license maintenance, registration transfers after acquisitions, and country-specific periodic updates. Markets such as Brazil (ANVISA), China (NMPA), South Korea (MFDS), India (CDSCO), Japan (PMDA), Australia (TGA), and Health Canada have diverse renewal cycles and documentation requirements. A device-first RIM should carry configurable renewal templates and automated advance-notice triggers for each market, not just FDA and EU.

FDA eSTAR structures 510(k) content as a set of form fields with attached documents rather than a free-form dossier. A RIM that supports eSTAR integration should map internal submission fields to eSTAR form fields and manage attachments so the final export is a well-formed package, reducing manual assembly errors. For teams that also submit eCTD sequences — for combination products or investigational device submissions with drug components — Assyro's eCTD submission workspace provides controlled sequence state management, complementing the device-side RIM for hybrid submission types.

IMDRF Table of Contents (ToC) alignment is also important for global harmonization. A RIM that structures technical documentation according to IMDRF ToC categories makes it easier to reuse document packages across participating markets without rebuilding the dossier for each.

UDI data management and submissions (FDA GUDID, EU EUDAMED)

UDI is a clear differentiator between device-specific RIMs and pharma-adapted platforms; proper UDI modeling prevents record proliferation and supports automated submissions. The UDI data model has a defined hierarchy — Basic UDI-DI (device family), UDI-DI (specific model/version), and UDI-PI (production specifics). A RIM must natively model all three levels, and the Basic UDI-DI must anchor the product family record that links country registrations, Notified Body certificates, and clinical evaluation reports.

Issuing agencies — GS1, HIBCC, and ICCBBA — use different carrier formats and data schemas. A RIM should record which issuing agency was used for each UDI-DI and carry the corresponding identifier in the device record because this is required for FDA GUDID and EU EUDAMED submissions. For FDA GUDID, the RIM should support direct API submission or structured export in the GUDID-compliant format, populated from device record attributes rather than manual re-entry. For EU EUDAMED, device registration and UDI modules require structured device attributes — including GMDN/EMDN code, EU MDR/IVDR risk classification, packaging levels, and labeling language declarations — that should be maintained as structured fields in the RIM.

A poor UDI data model leads to near-duplicate records: teams creating separate RIM records for each country variant without a shared Basic UDI-DI anchor produce dozens of divergent records. The data model section below addresses how to avoid that.

Notified Body certificates and surveillance

Notified Body certificate management is a critical, time-sensitive workflow for EU-targeting manufacturers; missing a renewal can prevent market placement. A RIM should store each CE certificate as a structured record linked to the relevant Basic UDI-DI family and EU MDR/IVDR product scope, including certificate number, issuing Notified Body, scope, issue date, and expiration date. Advance-notice alerts — typically 12 to 18 months before expiration — are essential because NB capacity is constrained and renewals require lead time. Missing an expiration without a replacement means the product cannot be legally placed on the EU market.

Scope expansions and changes require separate tracking. When a manufacturer adds a new size or configuration, the RIM should link the variant to the existing certificate while recording the scope amendment, amendment date, and associated Declaration of Conformity update. Unannounced audits require recording audit dates, scope, findings, and corrective action commitments so RA can provide an accurate account during surveillance visits.

Declaration of Conformity (DoC) version control is also critical. A DoC references specific standards and certificate numbers; when standards or certificates change, the DoC must be updated and the new version linked in the RIM. Managing this in email threads and shared folders creates version drift that leads to audit findings.

Post-market surveillance and vigilance (PMS, PMCF, PSUR, SSCP)

PMS workflows under EU MDR Articles 83–86 are a substantial ongoing burden that a properly configured RIM can reduce by structuring plans, reports, and signal workflows. The PMS plan, PMCF plan, PMCF evaluation report, PSUR, and SSCP must be version-controlled, linked to technical documentation, and updated on cycles defined by device risk class (for example, annually for Class III and implantable Class IIb). Keeping these records linked and scheduled avoids missed reporting obligations.

A device RIM delivers value in PMS when it ingests signals from adjacent systems — complaints from eQMS, service data from ERP or field service platforms, and literature monitoring outputs — and routes them into structured trend evaluation workflows. The outcome of that workflow determines whether a field safety corrective action (FSCA) is warranted, which triggers a vigilance report to the competent authority. The RIM should maintain a traceable thread from initial signal through trend evaluation, FSCA decision, competent authority notification, and SSCP update so the evidence chain is reconstructable during Notified Body surveillance.

For FDA, equivalent obligations include MDR (Medical Device Reporting) for individual events, trend reporting under 21 CFR 803/804, and post-approval study reporting for PMA devices. A RIM that treats PMS as a device-specific workflow — not an afterthought — links vigilance records directly to device records, registrations, and submission history so RA can answer "what did we know, when did we know it, and what did we do about it" without manual document assembly.

Change control and regulatory impact assessment

Change control is the workflow where RIM connections to PLM and eQMS deliver the most direct operational value by automating regulatory impact assessment and reducing release risk. When an engineering change order (ECO) is approved in PLM — a new material, dimensional tolerance update, or software version increment — the RIM should receive a structured notification and trigger an impact assessment against every active registration, labeling version, UDI record, and country-specific indication linked to the affected device. Without this automated trigger, regulatory impact is assessed manually and inconsistently, and changes can reach the market without required health authority notifications.

The RIM's impact assessment should apply market-specific rules. A change exempt from a new 510(k) in the US may still require a PMCN in Canada, a variation submission in the EU, or a full re-registration in China. The RIM needs to encode these thresholds or present RA with a structured checklist of markets and applicable change-notification requirements. The assessment's output should be a documented decision record that satisfies audit trail expectations under ISO 13485 and EU MDR Annex II.

Labeling changes deserve special handling. A UDI barcode update, language addition to an IFU, or revised intended use can each trigger country-specific review and approval obligations. The RIM should track labeling versions linked to registrations and flag when a labeling change requires regulatory action before distribution in a given market.

SaMD, cybersecurity, and documentation traceability

SaMD introduces documentation and cybersecurity requirements that generic RIMs often lack structure for; explicitly modeling SaMD lifecycle states in the RIM reduces oversight risk. Under IEC 62304 and harmonized guidance, a SaMD manufacturer must maintain a software development lifecycle plan, architecture documentation, integrated risk management and hazard analysis, and a problem resolution process. Under FDA cybersecurity guidance and EU MDR/IVDR expectations, manufacturers are expected to maintain a software bill of materials (SBOM), a vulnerability disclosure process, and a post-market patching plan.

In the RIM, SaMD traceability means linking a software version record — including IEC 62304 safety class, SBOM reference, and last vulnerability assessment date — to device registrations and submissions. For continuously deployed cloud-based SaMD, each software update that qualifies as a significant change may trigger a change assessment workflow, a submission or supplement, and a UDI-DI update if identity is affected. A RIM that supports SaMD-specific lifecycle states and change-assessment templates helps RA manage rolling obligations without losing the linkage between software version history and regulatory status.

Data model essentials: products, families, variants, and Basic UDI-DI

The data model is the foundation for every RIM workflow and the source of many implementation failures; getting it right prevents record proliferation and supports reuse across markets. The most common failure pattern is creating a separate product record for each country-market combination, which results in duplication without shared lineage. A sound device RIM data model anchors every product family to a single Basic UDI-DI record and hangs country registrations, Notified Body certificates, and labeling versions from that anchor rather than duplicating core device attributes.

A device family in the RIM should represent the set of devices sharing a Basic UDI-DI: same design, intended purpose, and family-level labeling. Individual models or configurations within the family are represented as UDI-DI records, each carrying attributes — catalog number, size, sterile/non-sterile, single use/reusable — that distinguish them from siblings. Country registrations are relationships between a UDI-DI (or subset of UDI-DIs in the family) and a market, with market-specific fields such as local registration number, classification code, license holder, and renewal date. This three-level hierarchy — Basic UDI-DI / UDI-DI / Registration — keeps record counts manageable while supporting required country-specific variation.

Distributor-held registrations add another layer: the license holder field must distinguish between manufacturer-held and distributor-held approvals, with fields for the distributor entity, regulatory contact, and contractual renewal obligations. Missing a distributor-held renewal because the RIM only tracked manufacturer-held approvals is a documented operational gap that proper modeling eliminates.

Field blueprint: mapping core device attributes to RIM objects

Start with a clear ownership model and map each required regulatory attribute to the appropriate RIM object. The following field checklist is organized by RIM object and based on the regulatory requirements of FDA GUDID and EU EUDAMED.

Basic UDI-DI record (family level):

• Basic UDI-DI code (issuing agency: GS1, HIBCC, or ICCBBA)
• Device name (reference name)
• GMDN code or EMDN code
• Risk classification (US: Class I/II/III; EU: Class I/IIa/IIb/III; IVD: A/B/C/D)
• Intended purpose statement
• Clinical evaluation report reference (EU MDR)
• PMS plan reference

UDI-DI record (model/version level):

• UDI-DI (issuing agency carrier format)
• Catalog/reference number
• Device description (model-level)
• Sterile packaging flag
• Single use flag
• MRI safety status
• Implantable flag
• Packaging level (unit, case, pallet)
• Labeling version reference
• Software version (if SaMD)

Registration record (market level):

• Market/country
• Registration number or approval reference
• License holder (manufacturer or distributor)
• Health authority or Notified Body
• Classification in-market
• Approval date
• Renewal date
• Registration status (active, pending, lapsed, withdrawn)
• Local indications or restrictions

Ownership of each field should be assigned during RIM implementation: Basic UDI-DI fields are typically owned by the regulatory data steward; UDI-DI technical attributes are sourced from PLM and confirmed by RA; registration records are owned by regional RA leads with steward oversight. The data stewardship model section addresses governance in more detail.

Integration patterns that work with PLM, eQMS, ERP, and labeling

Integration design is often the most underestimated phase of a device RIM implementation; reliable integrations are essential to avoid creating more manual work than the RIM eliminates. A RIM that cannot reliably receive product changes from PLM or surface regulatory status to ERP for order management creates manual reconciliation work and delays. The four critical integration points are PLM (product configuration and change control), eQMS (complaints, CAPAs, and controlled documents), ERP (product codes, license status for distribution control), and labeling systems (artwork versions, approved label text, and UDI barcode data). Health authority gateways — FDA GUDID, EU EUDAMED, and national registration portals — are often managed through structured data exports or direct API connections.

Agree the integration approach before vendor selection. API-first platforms are preferable because they enable bidirectional, event-driven exchange rather than scheduled batch uploads that introduce latency and version mismatches. Where real-time API is not available — for example, some national registration portals — the RIM should support structured export formats matching the portal's import template to reduce re-entry errors.

Who owns what data: a pragmatic master-data model

Defining the system of record prevents competing sources of truth that lead to operational failures. The following decision criteria reflect common practice and should be adapted to each organization's system footprint.

PLM as system of record for:

• Product identifiers (catalog numbers, part numbers, item codes)
• Bill of materials and component specifications
• Engineering configuration state and approved design version
• Change order history

eQMS as system of record for:

• Controlled document versions (SOPs, work instructions, test protocols)
• Design history file documents (risk management file, design V&V records)
• CAPA records and complaint investigations
• Supplier qualification records

RIM as system of record for:

• Basic UDI-DI and UDI-DI records (regulatory identity of the device)
• Registration records and approval status per market
• Submission records and correspondence with health authorities
• Notified Body certificates and Declaration of Conformity versions
• Post-market surveillance plan and report records
• Regulatory impact assessments linked to PLM change orders

ERP as system of record for:

• Customer-facing product codes and pricing
• Inventory and distribution records
• License hold flags (fed from RIM registration status)

Operational implication: when PLM initiates a change order, the RIM receives a notification and owns the regulatory impact assessment decision. When the RIM records a registration lapse, ERP should receive an automated flag to restrict distribution in that market. These bidirectional flows require API agreements and data governance policies — not just system configuration.

Validation, security, and audit readiness

Validation of a RIM used in a medical device regulatory context is a GxP obligation, not optional, and it directly affects inspection readiness and product compliance. The system processes regulated records — submissions, registration decisions, post-market reports — and the integrity of those records must be demonstrable during inspections and audits. Two frameworks guide this effort: GAMP 5 (2nd edition, 2022) and FDA's Computer Software Assurance (CSA) guidance (2022).

Both frameworks are risk-based but differ in emphasis. GAMP 5 provides a detailed categorization approach (Categories 1–5) and recommends lifecycle activities — user requirements specification, supplier assessment, configuration specification, testing, and change control — calibrated to complexity. FDA CSA shifts emphasis further toward risk-based thinking: it discourages documentation that adds no assurance value and encourages focusing testing on functionality that most directly impacts patient safety and product quality. For a cloud-based RIM, FDA CSA framing means concentrating validation on workflows supporting regulated submissions and records, not on every configuration option.

Risk-based validation (GAMP 5 vs FDA CSA): what to document

The validation deliverable set should reflect both regulatory context and the platform's GAMP 5 classification. A configured SaaS platform typically falls in Category 4 (configured software) under GAMP 5; if it includes custom workflows or code, it may approach Category 5. For FDA CSA, the key question is: "What critical thinking and testing are needed to provide adequate assurance?" not merely which documents are required.

A practical deliverable set, calibrated to risk:

• Supplier audit or qualification assessment (SOC 2 Type II report review, vendor questionnaire, or on-site audit as appropriate)
• User requirements specification (URS) focused on regulated workflows (submission management, registration records, UDI data, PMS tracking)
• Risk assessment mapping URS requirements to risk level (patient safety impact, submission integrity, audit trail)
• Configuration or design specification for workflows and data model
• Test strategy and traceability matrix linking requirements to test cases
• IQ/OQ test execution records for critical workflows (high-risk requirements)
• PQ evidence for end-to-end business scenarios (e.g., submission creation through regulatory impact assessment)
• Validation summary report
• Change control and periodic review procedures for the validated state

Under FDA CSA, you can reasonably reduce documentation for low-risk configurations (user preferences or report formatting) while maintaining thorough evidence for high-risk functions (submission status records, UDI data integrity, audit trail completeness). Auditors expecting CSA-aligned validation will look for documented risk rationale for scoping decisions, not unexplained documentation gaps.

21 CFR Part 11/Annex 11 expectations in practice

A device RIM that processes electronic records used in submissions or registration decisions must meet 21 CFR Part 11 (FDA) and Annex 11 (EU GMP, by analogy) expectations in practice, which directly impacts signature and audit-trail requirements. This means role-based access controls enforced at record and workflow level, a time-stamped and user-attributed audit trail for every create/modify/delete action on regulated records, and electronic signature capability linking a signature to the specific record version. Hybrid signatures — electronic signature on a printed document — are generally not acceptable for records originating in the RIM.

Cloud RIM vendors may claim Part 11 compliance, but the manufacturer's validation obligation is to verify claims through supplier qualification evidence (SOC 2 Type II, third-party reports) and to test Part 11 controls within the validated configuration. For EU Annex 11, expectations include formal change control over the validated state, periodic reviews, and documented business continuity provisions. RA teams should confirm these controls are in scope for the RIM's validation before go-live.

Implementation playbook and timeline

A device RIM implementation is a data and process project as much as a software project; underinvesting in data migration, workflow design, and change management is a common cause of delayed go-lives and low adoption. Organizations that focus primarily on platform configuration and neglect migration and governance typically experience data quality problems that undermine the system's credibility during audits. The implementation should be planned in phases with clear milestones, resourcing targets, and defined acceptance criteria for each phase.

For a mid-sized device manufacturer with 50–200 device families and registrations across 15–30 markets, a realistic full implementation timeline — from discovery through stable operations — is 12 to 18 months. Larger legacy portfolios, complex integrations, or significant data quality debt push timelines to the longer end or beyond.

Phases from discovery to go-live

A phased approach reduces risk by delivering value incrementally and surfacing integration and data-quality issues before they affect the critical path.

Phase 1 — Discovery and design (8–12 weeks): Define functional scope, map current-state processes, document integration requirements (PLM, eQMS, ERP, labeling, health authority gateways), and produce the URS. Identify data migration scope and assess data quality in source systems. Engage the vendor on configuration approach and supplier qualification evidence for validation.

Phase 2 — Configuration and build (10–16 weeks): Configure the RIM data model (Basic UDI-DI hierarchy, registration records, workflow templates), build and test integrations in a non-production environment, and complete IQ/OQ testing against the validation traceability matrix. Run a pilot data migration on a product family subset to validate cleansing rules and mapping logic.

Phase 3 — UAT and migration (8–12 weeks): Conduct user acceptance testing with RA, RegOps, and quality stakeholders on end-to-end scenarios. Complete full data migration from legacy sources, including deduplication and stewardship review. Finalize validation summary report and obtain quality/compliance sign-off.

Phase 4 — Go-live and stabilization (4–8 weeks): Deploy to production, execute the cutover plan, and provide hypercare support. Track adoption metrics (active users, records created per week, workflows completed) and resolve configuration gaps identified post-launch.

Data migration for legacy devices and Basic UDI-DI deduplication

Legacy portfolio migration is often the most time-consuming and highest-risk element of implementation and requires rigorous stewardship. Source data — typically spreadsheets, SharePoint folders, and legacy registration databases — often contains duplicate device records, inconsistent naming conventions, and missing or incorrect UDI-DI values. The Basic UDI-DI is particularly prone to duplication because different business units or acquired entities may have assigned values independently.

Begin with a data profiling exercise: identify all source systems, extract a candidate record set, and apply matching rules to detect duplicates based on device name, catalog number, and UDI-DI. Duplicates should be reviewed by a regulatory data steward — not resolved automatically — because canonical-record decisions require regulatory judgment, not just pattern matching. Once duplicates are resolved and a master record is established, migrate country registrations as children of the canonical device record and validate completeness against each market's required fields.

Stewardship controls must be in place before data goes live. Assign a data steward role with documented RACI to review and approve any new device record creation, UDI-DI modification, or registration record merge. Without these controls, deduplication performed during migration will erode as teams create ad hoc records to solve immediate problems.

Metrics, ROI, and governance

RIMs enable consistent performance measurement and a credible business case for regulatory operations investment by producing structured data that ties to cost, time, and risk metrics. Device RA teams have traditionally reported cycle time and lapses anecdotally; a well-configured RIM creates the data needed to quantify avoided costs, recovered time, and risk reduction in terms finance and operations leaders understand.

ROI for a device RIM is best framed around three categories of value: avoided cost (registration lapses, audit findings, submission rework), time recovery (eliminated manual status reporting, faster impact assessments), and risk reduction (complete audit trails, proactive renewal management). Tools such as regulatory ROI calculators can help configure baseline inputs and generate annualized impact estimates to support the business case.

KPIs RA teams can actually track in a RIM

Define KPIs in the RIM’s reporting configuration before go-live so baseline values are established from day one. Useful KPIs include:

• Right-first-time rate: Percentage of submissions accepted without an information request (IR). Calculated as accepted submissions without IR ÷ total submissions in the period.
• Submission cycle time: Calendar days from submission initiation in the RIM to health authority acceptance or clearance, measured by pathway.
• IR turnaround time: Calendar days from IR receipt (logged as health authority correspondence) to IR response submission.
• Renewal lead time: Days between renewal initiation in the RIM and submission of the renewal application to the authority, measured per market.
• Registration lapse rate: Percentage of active registrations that lapsed in a period; a non-zero rate in a mature RIM indicates workflow or resourcing issues.
• Open impact assessments: Count of PLM change orders pending regulatory impact assessment, aged by days open.

Data stewardship models: centralized vs regional

Governance has long-term quality consequences and should match organization size and maturity. In a centralized model, a small team of regulatory data stewards owns and approves all device record creation, modification, and deactivation in the RIM. Regional RA leads own registration records for their markets but cannot create new product records unilaterally. This model yields high consistency and low duplication but can bottleneck changes if steward capacity is limited.

In a regional model, RA leads in each geography have broader create and edit rights, with stewards performing periodic audits rather than transaction-level controls. This scales for large, distributed portfolios but increases the risk of record divergence and duplication. A hybrid approach — centralized stewardship for Basic UDI-DI and UDI-DI records, regional ownership for registration records — is the most common pattern. Escalation paths should be documented, with defined SLAs (typically 48–72 hours) for steward review to prevent local workaround records.

RIM vs eQMS vs PLM: which system should lead for devices?

No single system should try to lead for all regulatory data; PLM, eQMS, and RIM have complementary roles that should hand off cleanly rather than overlap. PLM manages physical and logical product configurations over the engineering lifecycle — BOMs, revision control, configuration management, and change orders — but does not natively model health authority relationships, submission dossiers, or UDI hierarchies. eQMS manages quality processes — document control, CAPA, complaints, audits, supplier management, and training — and holds controlled documents that feed submissions, but it does not track which document version was submitted to which authority or the current regulatory status of approvals.

RIM manages the regulatory relationship between product and health authority across markets: it receives structured output from PLM and eQMS, assembles and tracks submissions, records approval decisions, manages renewals, and provides the audit trail auditors expect. It should not attempt to perform core quality event tracking (eQMS's job) or configuration management (PLM's job).

Practical decision rule: if the attribute answers "what is this product built from and how is it configured?", it belongs in PLM. If it answers "is this document approved and version controlled?", it belongs in eQMS. If it answers "what is the current regulatory status of this device in this market, and what submissions and obligations are associated with it?", it belongs in the RIM.

Buyer checklist: evaluate medical device RIM capabilities

This checklist is designed for vendor evaluation. Prioritize must-have items (M) before assessing nice-to-have capabilities (N). A platform that cannot satisfy must-have items for your portfolio and markets is not viable regardless of its other features.

UDI and product data model:

• M: Native Basic UDI-DI / UDI-DI / UDI-PI hierarchy with family-level anchoring
• M: Structured fields for GS1/HIBCC/ICCBBA issuing agency, GMDN/EMDN code, risk classification, packaging levels
• M: Outbound FDA GUDID submission support (API or structured export)
• M: EU EUDAMED device and UDI module data fields with structured export or API
• N: Automated UDI barcode label data validation against registration record

Submission management:

• M: Device-specific submission templates for 510(k), De Novo, PMA, EU MDR Annex II/III technical documentation, IVDR
• M: FDA eSTAR form field mapping with document attachment management
• M: IMDRF ToC-aligned document structure for multi-market dossier reuse
• M: Health authority correspondence tracking (IR/deficiency receipt, response assembly, submission of response)
• N: AI-assisted submission content drafting with clause-level requirement awareness

Notified Body and EU compliance:

• M: CE certificate record with fields for NB, certificate number, scope, expiration, and advance-notice alerts
• M: Scope expansion and Declaration of Conformity version tracking linked to certificate record
• M: Surveillance audit tracking (scheduled and unannounced) with findings and corrective action records
• N: EUDAMED certificate status synchronization

Post-market surveillance:

• M: PMS plan and PMCF plan records linked to Basic UDI-DI family
• M: PSUR and SSCP version tracking with due-date alerts by device risk class
• M: Vigilance/FSCA record with competent authority notification tracking
• N: Signal ingestion workflow from complaints/eQMS with structured trend evaluation

Registrations and renewals:

• M: Registration record per market with license holder, renewal date, and advance-notice alerts
• M: Distributor-held registration support with license holder field and obligation tracking
• M: Multi-market registration status dashboard with filter by status, market, and expiration horizon
• N: Country-specific renewal template library for ANVISA, NMPA, TGA, MFDS, CDSCO, PMDA, Health Canada

Change control and regulatory intelligence:

• M: Change impact assessment workflow triggered by PLM change order notification
• M: Market-specific impact rules (configurable thresholds for new submission vs. notification vs. file-to-record)
• M: Standards and regulation monitoring with configurable product scope alerts
• N: Automatic linkage from impact assessment decision to affected registration and labeling records

Integrations:

• M: API for bidirectional integration with PLM (product/configuration data and change order notification)
• M: API or structured interface with eQMS (controlled documents, complaints/CAPAs)
• M: Registration status export to ERP for distribution control
• N: Labeling system integration for artwork version and UDI barcode data

Validation and security:

• M: SOC 2 Type II attestation or equivalent supplier qualification evidence
• M: 21 CFR Part 11 and EU Annex 11 compliant audit trail (time-stamped, user-attributed, immutable)
• M: Role-based access control with configurable permission sets by record type and geography
• M: Validation package support (IQ/OQ test scripts, configuration specification, supplier evidence)
• N: GAMP 5 Category 4/5 validation documentation templates provided by vendor

SaMD and cybersecurity:

• N: Software version record with IEC 62304 safety class, SBOM reference, and change assessment linkage
• N: Continuous deployment change assessment workflow with configurable significance thresholds

For device teams submitting eCTD sequences — for example, combination product IDE applications or submissions requiring eCTD format — Assyro's submission workspace provides structural checks across Modules 1–5, with lifecycle, hyperlink, metadata, and checksum manifest validation running locally so confidential dossier content remains controlled. That capability addresses structural readiness for eCTD-format submissions and complements the registration and UDI management functions of a dedicated device RIM.